None listed
Conditions
Interventions
recombinant human lysozyme Type of group
Rice-based ORS will be administered with 0.2 mg / mL of recombinant human lizosima.
Group name:recombinant human lactoferrin Type of group
Rice-based ORS will be administered with 1 mg / mL recombinant human lactoferrin.
Sponsors
Ventria Bioscience,
Eligibility
Inclusion criteria
Inclusion criteria: • Boys, 4 to 36 months of age • Acute acute watery diarrhea in the last 72 hours • Mild or moderate dehydration • Can tolerate liquids • No episodes of diarrhea during the 2 weeks prior to the beginning of the episode current diarrhea • You have not taken antibiotics during the current episode of diarrhea. • The child wears or tolerates diapers and urine collection bags. • Parents agree that their children use urine collection bags in addition to diapers • Parents willing to give written consent and allow home visits
Exclusion criteria
Exclusion criteria: • Presence of any chronic disease or systemic infection • Severe malnutrition (W / H - <2 ZS; Kwashiorkor / marasmus) • Blood visible in the stools. • Known allergy to rice or rice products. • Exclusive breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:volume and characteristics of bowel movements, through the use and weighing of disposable diapers; of diuresis through the use of urine collection bags, of the volume consumed of ORS, of any vomit that could present. Measure:Compare the glucose-based oral rehydration solution with a rice-based ORS and a rice-based ORS containing recombinant human lactoferrin (rhLF) and recombinant human lysozyme (rhLY) in concentrations similar to those found in milk maternal Timepoints:14 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated | — |
Countries
Peru, United States
Outcome results
None listed